Oncology Devices Market
Report ID: SQMIG35A4197
Report ID: SQMIG35A4197
[email protected]
USA +1 351-333-4748
Report ID:
SQMIG35A4197 |
Region:
Global |
Published Date: July, 2026
Pages:
157
|Tables:
161
|Figures:
78
Global Oncology Devices Market size was valued at USD 152.48 Billion in 2024 and is poised to grow from USD 161.9 Billion in 2025 to USD 261.58 Billion by 2033, growing at a CAGR of 6.18% during the forecast period (2026-2033).
The global oncology devices market is made up of the equipment used for cancer detection, treatment and monitoring, ranging from imaging scanners to radiation therapy systems. Its significance is driven by the increasing prevalence of cancer, aging demographics and escalating healthcare costs globally. The market of today has evolved from simple X-ray units in the 1960s to sophisticated linear accelerators and AI-enhanced diagnostic platforms. One of the main drivers of this growth is the rise in early stage diagnosis that drives the demand for minimally invasive tools. Take PET‑CT in North America, where the adoption rate grew 18% per year from 2015 to 2022, illustrating how need and technology reinforce each other.
Apart from diagnosis, the growth engine of a key market is the expansion of personalized radiotherapy devices as clinicians seek treatment intensity aligned with tumor genetics. Hospitals are being forced to upgrade aging machines and invest more capital. Advanced linear accelerators with image-guided radiation therapy (IGRT) reduce collateral damage. This change is evident in Europe, where the adoption of MR‑linac systems increased by 22 % in 2023, allowing for adaptive dose modulation for prostate and pancreatic cancers and lowering complication rates. This gives vendors that combine software analytics and remote maintenance a competitive edge and makes insurers more likely to pay for outcomes-based contracts, which in turn encourages further investment in advanced oncology hardware.
How is AI Integration Improving Outcomes In The Oncology Devices Market?
AI integration is transforming oncology devices with smarter imaging, precise therapy delivery and real time decision support. Machine learning algorithms scan the images to identify the characteristics of the tumor and assist clinicians in creating a tailored treatment plan. Predictive models reduce unnecessary procedures and improve safety by predicting patient response. Today’s platforms combine AI with radiation machines, surgical robots and diagnostic scanners for a seamless workflow from diagnosis to follow up. Companies are integrating AI into hardware to automate dose calculations, improve image clarity and streamline workflows, accelerating clinical trials and broadening access to advanced care.
Now, as clinicians are able to see real benefits to patient outcomes, the market expects a faster adoption. Varian, in March 2024, introduced an AI-driven treatment planning system that automatically optimizes radiation dose distribution, thereby reducing planning time and enhancing tumor targeting. The development demonstrates how AI can help streamline workflows, improve accuracy and drive growth in the oncology devices market.
Market snapshot - (2026-2033)
Global Market Size
USD 152.48 Billion
Largest Segment
Treatment Devices
Fastest Growth
Interventional Oncology Devices
Growth Rate
6.18% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global oncology devices market is segmented by product type, cancer type, technology, application, end user and region. Based on product type, the market is segmented into Diagnostic Devices, Treatment Devices, Surgical Oncology Devices, Interventional Oncology Devices and Supportive Care Devices. Based on cancer type, the market is segmented into Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Gynecological Cancer, Hematological Cancers, Brain Cancer, Liver Cancer, Skin Cancer and Others. Based on technology, the market is segmented into Radiation Therapy, Imaging-Guided Oncology, Thermal Ablation, Cryoablation, Electrosurgery, Robotic-Assisted Oncology, Laser-Based Oncology and Others. Based on application, the market is segmented into Cancer Diagnosis, Cancer Treatment, Tumor Monitoring & Follow-up and Palliative Care. Based on end user, the market is segmented into Hospitals, Specialty Cancer Centers, Ambulatory Surgical Centers, Diagnostic Imaging Centers and Research & Academic Institutes. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
The diagnostic devices segment is dominant, as clinicians depend on precise early detection to guide treatment pathways, and improvements in molecular imaging and liquid biopsy have boosted clinical confidence. The ability to provide rapid, minimally invasive results improves patient triage and reduces downstream costs, motivating hospitals and cancer centers to prioritize investment in these solutions. Constant innovations in assay sensitivity and data analytics further strengthen the oncology devices market.
However, Treatment devices segment is witnessing the highest growth momentum as emerging minimally invasive therapies and personalized radiotherapy platforms are expanding clinical adoption. Real time imaging and adaptive dosing are fueling physician confidence and reimbursement reforms are spurring acquisition. The fast adoption of this is driving wider market growth and new opportunities for device makers to differentiate on integrated software solutions.
The robotic assisted oncology segment is poised to gain momentum due to the integration of precision mechanics with cutting-edge imaging, allowing surgeons to execute intricate tumor resections with improved dexterity. Major hospitals are investing in these systems because they reduce operative trauma, shorten hospital stays and satisfy the demand for minimally invasive interventions. Its ability to embed AI enabled planning only further cements its critical position in the oncology devices market.
The imaging guided oncology segment is emerging as the key high growth area with advances in hybrid imaging and real time navigation broadening its clinical utility across tumor types. The market is witnessing growth due to the adoption momentum of continuous improvements in resolution and software analytics in academic and community practices, opening new spaces for innovation.
To get detailed segments analysis, Request a Free Sample Report
North America is dominating the Oncology Devices Market due to its strong research capabilities, large clinical infrastructure, and strong reimbursement systems that support the rapid adoption of advanced technologies. There is a high density of world-class academic medical centers in the area that are constantly generating high-quality evidence, which builds clinician confidence. Strong relationships between device manufacturers and health systems accelerate product introduction and integration, while a smart regulatory environment ensures timely approvals. And a culture of innovation, backed by huge amounts of venture capital, creates a pipeline of state-of-the-art solutions. The region’s status as the market benchmark is reinforced by patient-centric healthcare models, comprehensive insurer coverage and a proactive approach to the incorporation of digital health tools.
The oncology devices market in the United States is a mature ecosystem, with leading manufacturers, academic institutions and large health networks working intensively together. The payer landscape is sophisticated and incentivizes value-based outcomes, which in turn supports rapid clinical trials and early adoption of novel platforms. Strong intellectual property protections fuel innovation, and continued investment in research and development keeps the stream of next-generation devices coming. A pre-existing precision medicine culture also facilitates the implementation of targeted technologies into treatment pathways.
The Oncology Devices Market in Canada is characterized by a balanced approach of strong public healthcare funding and focus on equitable access. Provincial health authorities are actively assessing and implementing new technologies, promoting systematic deployment according to evidence-based guidelines. Collaborative networks between research centers and hospitals promote knowledge sharing and joint clinical studies that facilitate the deployment of new devices. Procurement decisions are primarily driven by cost-effectiveness and benefits to patient and create fertile ground for sustainable market growth in Canada.
Europe experiences rapid expansion of the Oncology Devices Market thanks to harmonized regulatory standards that simplify cross‑border product entry and encourage multinational collaborations. Public health systems across the region allocate substantial resources toward modernizing oncology care, creating demand for advanced diagnostic and therapeutic tools. Robust research consortia bring together academia, industry, and clinical practitioners, generating a fertile ground for co‑development of cutting‑edge solutions. Emphasis on personalized treatment pathways drives interest in devices that enable precise tumor profiling and minimally invasive interventions. Furthermore, a growing emphasis on digital integration supports the adoption of smart platforms that enhance workflow efficiency and patient monitoring, reinforcing Europe’s position as a dynamic growth hub.
Oncology Devices Market in Germany stands out for its strong industrial base and extensive clinical trial capacity. The country’s hospitals and research institutes work closely with manufacturers to test and refine high‑performance solutions, fostering rapid technology iteration. A supportive reimbursement framework facilitates timely incorporation of innovative devices, while a focus on precision oncology drives demand for advanced imaging and targeted delivery systems. Collaborative clustering of biotech and medical‑device firms further accelerates product development pipelines.
Oncology Devices Market in the United Kingdom is propelled by an ambitious agenda that emphasizes early adoption of breakthrough technologies. National health services prioritize evidence‑based integration of novel devices, creating a receptive environment for innovative offerings. Strong ties between leading academic hospitals and industry partners enable rapid clinical validation, while a vibrant startup ecosystem injects fresh ideas into the market. Commitment to personalized care pathways fuels interest in platforms that support real‑time data analytics and individualized treatment planning.
Oncology Devices Market in France is emerging as a fertile ground for next‑generation solutions, bolstered by proactive public‑private partnerships. The healthcare system encourages the evaluation of innovative devices through structured assessment pathways, supporting gradual market entry. French research centers excel in translational studies that bridge laboratory discoveries with clinical practice, enhancing the relevance of new technologies. An increasing focus on patient‑centred care and outcome optimization drives demand for devices that improve precision and reduce treatment burden.
Asia Pacific strengthens its position in the Oncology Devices Market by building robust healthcare infrastructure and encouraging policy frameworks that stimulate domestic innovation. Governments across the region prioritize the development of high‑technology medical sectors, offering incentives that attract both multinational and local manufacturers. Growing clinical networks and a surge in oncology incidence create a receptive market for advanced diagnostic and therapeutic devices. Emphasis on cost‑effective solutions aligns with broader goals of expanding access while maintaining quality. Strategic collaborations between research institutions and industry accelerate technology transfer, and a rising focus on digital health integration further enhances the region’s capability to deliver sophisticated oncology care.
Oncology Devices Market in Japan benefits from a well‑established network of leading hospitals and research universities that champion early adoption of sophisticated technologies. The market places high value on reliability and precision, driving manufacturers to tailor devices to stringent quality expectations. Collaborative initiatives between government agencies and industry promote the development of cutting‑edge platforms, especially in minimally invasive surgery and imaging. A strong emphasis on patient safety and outcomes underpins procurement decisions, reinforcing Japan’s reputation for rigorous clinical standards.
Oncology Devices Market in South Korea is distinguished by rapid technological assimilation supported by forward‑looking health policies. The country’s advanced manufacturing capabilities enable swift scaling of innovative devices, while close ties between academic hospitals and biotech firms foster continuous product refinement. Government incentives encourage research into novel therapeutic modalities, positioning South Korea as a hub for emerging oncology technologies. Focused investment in digital integration and real‑time monitoring tools further enhances the efficiency and effectiveness of cancer treatment delivery.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Increasing Cancer Incidence Worldwide
Advances In Minimally Invasive Surgery
High Cost Of Advanced Devices
Regulatory Approval Complexity
Request Free Customization of this report to help us to meet your business objectives.
The oncology devices market remains highly competitive, led by companies such as Medtronic, GE Healthcare, Siemens Healthineers, Varian (Siemens), Elekta, Philips, Hologic, Accuray, Stryker, Eckert & Ziegler BEBIG, and Johnson & Johnson, alongside diagnostics-focused players. Product development remains the primary lever, with firms racing to launch AI-enabled imaging, precision radiotherapy, and minimally invasive ablation systems; for instance, ZEISS achieved FDA clearance for its INTRABEAM 7 system in April 2025 as part of a broader industry push toward precision-oriented treatments that improve patient safety and clinical workflow efficiency. Mergers and acquisitions continue to consolidate capabilities in imaging, radiation therapy, and surgical robotics, as larger players absorb niche innovators to broaden portfolios and geographic reach. Beyond M&A, companies are pursuing strategic partnerships, licensing deals, and regional distribution alliances to expand into Asia-Pacific and emerging markets, where cancer incidence is rising sharply. Other strategies include heavy R&D investment in liquid biopsy, digital pathology, and next-generation sequencing, along with regulatory-focused efforts to navigate stringent approval pathways. Overall, the competitive landscape is shaped by innovation intensity, consolidation, and expanding demand for personalized, technology-driven cancer care solutions worldwide.
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, the global oncology devices market is being propelled primarily by the rising worldwide incidence of cancer, which pushes hospitals and clinics to expand their diagnostic and therapeutic equipment portfolios. A second strong catalyst is the rapid advance of minimally invasive surgical technologies that improve outcomes and shorten stays, encouraging capital investment in robotic and laser‑based systems. High acquisition costs of cutting‑edge devices remain a notable restraint, especially for providers in cost‑constrained settings. North America continues to dominate the market due to its extensive clinical infrastructure, robust reimbursement and early‑adopter culture, while diagnostic devices hold the largest share as clinicians rely on precise early detection to steer treatment pathways.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 152.48 Billion |
| Market size value in 2033 | USD 261.58 Billion |
| Growth Rate | 6.18% |
| Base year | 2024 |
| Forecast period | (2026-2033) |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Oncology Devices Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Oncology Devices Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Oncology Devices Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Oncology Devices Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Global Oncology Devices Market size was valued at USD 152.48 Billion in 2024 and is poised to grow from USD 161.9 Billion in 2025 to USD 261.58 Billion by 2033, growing at a CAGR of 6.18% during the forecast period (2026-2033).
Top Player’s Company Profile 'Siemens Healthineers AG', 'Elekta AB', 'Accuray Incorporated', 'Becton Dickinson and Company', 'Medtronic plc', 'Johnson & Johnson', 'Stryker Corporation', 'Boston Scientific Corporation', 'F Hoffmann-La Roche Ltd', 'GE HealthCare Technologies Inc', 'Koninklijke Philips NV', 'Intuitive Surgical Inc', 'Olympus Corporation', 'Bard Medical', 'C R Bard Inc', 'AngioDynamics Inc', 'Merit Medical Systems Inc', 'Theragenics Corporation', 'Eckert & Ziegler AG', 'IBA Proton Therapy'
The rising prevalence of cancer across all age groups creates a sustained demand for diagnostic and therapeutic equipment, prompting hospitals and clinics to expand their oncology device portfolios. Health systems respond by adopting newer imaging, radiotherapy, and surgical platforms to improve patient outcomes and operational efficiency. This ongoing need fuels continuous procurement cycles, encourages manufacturers to launch innovative products, and supports long‑term market expansion as providers seek comprehensive solutions for an increasingly affected population. The broader awareness of early detection also reinforces investment decisions by administrators.
Ai‑Driven Personalized Imaging: Healthcare providers are integrating artificial intelligence into oncology imaging platforms to tailor diagnostic pathways for individual patients. Machine‑learning models analyze radiographic patterns, histopathology slides, and clinical histories, enabling earlier detection of subtle tumor signatures and more accurate staging. This shift reduces reliance on generic protocols, improves therapeutic alignment, and accelerates decision‑making across multidisciplinary teams. Providers cite enhanced confidence in treatment selection and the ability to monitor response dynamically as primary benefits, driving broader adoption of AI‑enhanced devices in clinical practice.
Why does North America Dominate the Global Oncology Devices Market? |@12
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
